| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -3,287,051 | -1,428,642 | -1,949,046 | 512,977 |
| Depreciation and amortization expense | 1,276,283 | 1,041,895 | 1,037,804 | 2,065,502 |
| Amortization of operating lease right-of-use asset | 285,184 | 285,185 | 285,184 | 570,369 |
| Loss on co-commercialization investment | NaN | -13,220 | NaN | NaN |
| Disposal of assets | NaN | 0 | NaN | NaN |
| Co-commercialization investment loss | -146,080 | NaN | NaN | NaN |
| Share-based compensation | 106,842 | 172,160 | 81,262 | 154,898 |
| Increase (decrease) in non-cash contingent consideration | -228,965 | -46,660 | 9,651 | 83,578 |
| Increase in cash surrender value of life insurance policies over premiums paid | NaN | 142,927 | NaN | NaN |
| Decrease in cash surrender value of life insurance policies over premiums paid | -218,916 | NaN | 91,460 | 40,507 |
| Noncash interest expense | 5,173 | 7,100 | 5,362 | 10,723 |
| Loss on disposal of assets | NaN | NaN | 0 | NaN |
| Life insurance proceeds | NaN | 0 | 0 | NaN |
| Accounts receivable | -2,682,802 | 6,514,178 | 113,691 | -1,384,555 |
| Inventories, net | -703,861 | 205,989 | -630,409 | -1,818,196 |
| Other current assets and other assets | -384,152 | 1,050,788 | -178,936 | -640,023 |
| Operating lease liabilities | -225,351 | -173,983 | -221,675 | -440,442 |
| Accounts payable and other current liabilities | -1,346,113 | 8,043,897 | 684,224 | -2,018,925 |
| Other long-term liabilities | -202,821 | -129,233 | -349,780 | 1,371 |
| Net cash provided by operating activities | 387,025 | 3,024 | 187,180 | 4,742,318 |
| Additions to property and equipment | 0 | -1 | 23,788 | 74,116 |
| Net investment in manufacturing | NaN | 1,029,497 | 611,600 | 836,095 |
| Life insurance policy proceeds received | NaN | 0 | 0 | NaN |
| Other investment | NaN | 2,000,000 | NaN | NaN |
| Increase in cash surrender value of life insurance policies | 42,018 | 0 | 47,000 | NaN |
| Net (increase) decrease of investment in manufacturing | 0 | NaN | NaN | NaN |
| Additions to intangible assets | 19,155 | 43,842 | 8,449 | 32,111 |
| Net cash provided by (used in) investing activities | -61,173 | -3,073,338 | -690,837 | -942,322 |
| Proceeds from atm offering, net | 0 | 0 | 0 | -5,266,334 |
| Borrowings on line of credit | NaN | 0 | 0 | 0 |
| Payments on line of credit | 0 | 0 | 0 | 10,035,437 |
| Cash settlement of contingent consideration | 702,299 | 681,738 | 376,440 | 654,757 |
| Payments made in connection with repurchase of common shares | 61,001 | 0 | 10,439 | 253,039 |
| Net cash used in financing activities | -763,300 | -681,738 | -386,879 | -5,676,899 |
| Net decrease in cash and cash equivalents | -437,448 | -3,752,052 | -890,536 | -1,876,903 |
| Cash and cash equivalents at beginning of period | 11,444,693 | 15,196,745 | 17,964,184 | NaN |
| Cash and cash equivalents at end of period | 11,007,245 | 11,444,693 | 15,196,745 | NaN |
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)